Search Results
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
pembrolizumab (KEYTRUDA®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated
More news about: Kelun-Biotech
May 21, 2026, 08:39 ET Alaska Airlines advances global expansion with launch of new European routes and landmark lounge investment
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."FAQ:Does Alaska Airlines fly to Europe? Yes. Alaska Airlines now offers nonstop service from its main hub in Seattle
More news about: Alaska Airlines
May 21, 2026, 08:17 ET Alaska Airlines advances global expansion with launch of new European routes and landmark lounge investment
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."FAQ:Does Alaska Airlines fly to Europe? Yes. Alaska Airlines now offers nonstop service from its main hub in Seattle
More news about: Alaska Airlines
May 21, 2026, 03:14 ET Datar Cancer Genetics recibe una histórica aprobación de la FDA estadounidense para CellDx-Tissue
autorización reconoce el flujo de trabajo de ADN y ARN de doble analito de CellDx-Tissue en 517 genes asociados al cáncer, con llamadas de fusión de ALK, RET y ROS1 basadas en evidencia a nivel de ARN.NASHIK, India, 21 de mayo
More news about: Datar Cancer Genetics
May 19, 2026, 09:30 ET Funding from Patients, Caregivers, Foundations and Industry Partners Fuels ALK-positive Research
better options for people living with ALK-positive lung cancer. Leading the fundraising effort was Colleen Conner Ziegler, chair of LCRF's board of directors and ALK-positive lung cancer survivor, the Murgatroyd family, who lost their daughter at the age of 24 to ALK-positive lung cancer, David Cornbrooks,
More news about: Lung Cancer Research Foundation
May 18, 2026, 12:30 ET OMNY Health Surpasses 175 Million Patient Milestone; Launches Oncology Product Suite to Solve Complex Real-World Evidence Gaps
survivorship.Precision Variables: Direct access to granular data including tumor staging, treatment plans, mutation data, and molecular biomarkers (e.g., EGFR, ALK, PD-L1).Auditability & Provenance: A transparent digital "paper trail" connects every data point to its source clinical event, ensuring
More news about: OMNY Health
May 18, 2026, 00:18 ET Datar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren
CellDx-Tissue als umfassende DNA- und RNA-basierte Genomprofiling-Lösung zur Analyse von 517 krebsrelevanten Genen einschließlich wichtiger Genfusionen wie ALK, RET und ROS1.NASHIK, Indien, 18. Mai 2026 /PRNewswire/ -- Datar
More news about: Datar Cancer Genetics
May 15, 2026, 10:00 ET Datar Cancer Genetics 的 CellDx-Tissue 獲得美國 FDA 核准，為該項利用 DNA 與 RNA 進行的實體腫瘤全方位基因體分析檢測寫下里程碑
是次核准認定了 CellDx-Tissue 的 DNA 與 RNA 雙分析物工作流程，涵蓋 517 個與癌症相關的基因，並能以 RNA 層級證據偵測 ALK、RET 與 ROS1 等關鍵融合基因印度納西克2026年5月15日 /美通社/ -- 全球精準腫瘤醫學公司 Datar Cancer Genetics (DCG) 今日宣佈，其適用於所有實體腫瘤、以組織為基礎的全方位基因體分析 (comprehensive
More news about: Datar Cancer Genetics
May 15, 2026, 09:59 ET Datar Cancer Genetics reçoit l'autorisation de la FDA des États-Unis pour CellDx-Tissue, un test de profilage génomique complet pour les tumeurs solides utilisant l'ADN et l'ARN
le processus de double analyse de l'ADN et de l'ARN de CellDx-Tissue portant sur 517 gènes associés au cancer, avec des appels de fusion ALK, RET et ROS1 au niveau de l'ARNNASHIK, Inde, 15 mai 2026 /PRNewswire/
More news about: Datar Cancer Genetics
May 14, 2026, 11:48 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level EvidenceNASHIK, India, May 14, 2026 /PRNewswire/
More news about: Datar Cancer Genetics
May 14, 2026, 11:39 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level EvidenceNASHIK, India, May 14, 2026 /PRNewswire/
More news about: Datar Cancer Genetics
May 12, 2026, 02:08 ET GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena
mechanism, but has also advanced multiple parallel programs and modalities, including combinations of BGM0504 with amylin, an MSTN cyclic peptide, an ALK7-targeting siRNA, and several oral formulations. The goal is to assemble a systematic set of capabilities spanning adipose tissue, muscle, bone metabolism,
More news about: BrightGene
May 11, 2026, 06:00 ET Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
FusionsNRG1 fusions are unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activate downstream signaling pathways that
More news about: Partner Therapeutics, Inc.
May 08, 2026, 06:40 ET The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative. This acceptance is based on the positive results from the OptiTROP-Lung05 registrational Phase III study, and the application is the fifth indication
More news about: Kelun-Biotech
May 07, 2026, 08:00 ET California dreaming - Alaska Airlines expands route network from Santa Rosa and returns to Long Beach with connection to Seattle
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
May 07, 2026, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
submitted an NDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive NSCLC to the FDA. The application is based on data in TKI pre-treated patients with advanced ALK-positive NSCLC treated with neladalkib in the global, registration-directed
More news about: Nuvalent, Inc.
May 06, 2026, 09:29 ET Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma
unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activate downstream signaling pathways that cause cancer
More news about: Partner Therapeutics, Inc.
May 05, 2026, 08:00 ET Frontier Airlines Reports First Quarter 2026 Financial Results
America's High-Value Airline.End Notes1 Industry average weighted by ASMs in FY2025 to include DAL, UAL, AAL, LUV, JBLU, ALK, and ALGT. Fuel efficiency is measured by ASMs per fuel gallon consumed.Cautionary Statement Regarding Forward-Looking Statements and InformationCertain
More news about: Frontier Group Holdings, Inc.
Apr 29, 2026, 08:10 ET Benvenuti! Alaska Airlines startet den historischen ersten Direktflug zwischen Seattle und Rom
news.alaskaair.com. Die Alaska Air Group wird an der New Yorker Börse (NYSE) unter dem Kürzel „ALK" gehandelt.
More news about: Alaska Airlines
Apr 28, 2026, 14:17 ET Benvenuti ! Alaska Airlines lance le premier vol historique sans escale de Seattle à Rome
news.alaskaair.com. Le groupe Alaska Air est coté à la bourse de New York (NYSE) sous le nom de « ALK ».
More news about: Alaska Airlines
Apr 28, 2026, 12:13 ET ¡Bienvenidos! Alaska Airlines lanza el histórico primer vuelo sin escalas entre Seattle y Roma
news.alaskaair.com. Alaska Air Group cotiza en la Bolsa de Valores de Nueva York (NYSE) con el símbolo "ALK".
More news about: Alaska Airlines
Apr 28, 2026, 10:54 ET Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
(SAF-189), Fosun Pharma's Class 1 innovative drug, was accepted by the NMPA, intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), expected to provide a new option for precision treatment of lung cancer. In
More news about: Fosun Pharma
Apr 28, 2026, 08:00 ET Benvenuti! Alaska Airlines launches historic first nonstop flight between Seattle and Rome
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Apr 28, 2026, 08:00 ET Benvenuti! Alaska Airlines launches historic first nonstop flight between Seattle and Rome
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Apr 27, 2026, 07:55 ET Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals, Co. Ltd. (Betta). It is indicated for the treatment of adult patients with ALK-positive locally advanced or metastatic NSCLC as detected by an FDA-approved test who have not previously received an ALK inhibitor and is
More news about: EVERSANA